Colorado State University/
Tufts University

The Flint Animal Cancer Center at Colorado State University together with the Cummings Veterinary Medicine Center at Tufts University are conducting studies to assess the efficacy of combination immunotherapy approaches to treatment and prevention of tumor metastasis in dogs with osteosarcoma.  These studies are being done in dogs with measurable osteosarcoma metastases, which will allow ready detection of treatment efficacy in a rapid time frame.

Principle Investigators:

Dr. Steven Dow,  veterinarian trained in immunology, microbiology, and cancer research, Flint Animal Cancer Center at Colorado State University

Dr. Cheryl London, veterinary medical oncologist trained in immunology,
Cummings Veterinary Medicine Center at Tufts University

Flint Animal Cancer Center at
Colorado State University
300 W Drake Rd.
Fort Collins, CO  80525

https://www.csuanimalcancercenter.org/

Cumming Veterinary Medical Center
at Tufts University
200 Westboro Rd.
N. Grafton, MA 01536

vetmed.tufts.edu

Contact for Clinical Trials Information: csuoncologytrials@colostate.edu
or call (970) 297-4001.

University of Alabama at Birmingham

Dr. Renee Chambers, DVM, MD, a surgeon and veterinarian at The University of Alabama at Birmingham (UAB) - is partnering with veterinarians to conduct the first immunotherapy study for brain tumors in dogs using an oncolytic herpes simplex virus known as M032. The virus, developed at UAB, is currently being used in a clinical trial to treat humans with the same tumors. Care for pet dogs is now available at regional sites, including the Colleges of Veterinary Medicine at Mississippi State, Georgia and Auburn. This trial opens up an exciting new research pathway while providing the potential of a therapy that could benefit both humans and canines with brain tumors.

Principle Investigator:

The University of Alabama at Birmingham
1720 2nd Avenue South
Birmingham, AL 35294-3410
https://www.uab.edu/medicine/caninetrial/

Study and contact information:
uab.edu/medicine/caninetrial
or call (205) 975-7519

UC Davis

Investigators at the UC Davis Comprehensive Cancer Center have teamed up with the UC Davis School of Veterinary Medicine to launch a series of investigative immunotherapy trials aimed at enhancing a patient’s own natural killer cells using inhaled recombinant IL-15 and super-agonist IL-15 in naturally occurring canine cancers.   The purpose of this study is to determine the maximum tolerated dose and efficacy of an immunotherapy protocol against metastatic osteosarcoma or melanoma growing within the lungs.

Principle Investigator:

University of California Davis School of Veterinary Medicine
944 Garrod Dr.
Davis, CA 95616

Contact:  oncologyclinicaltrials@ucdavis.edu 
(530) 752-0125 • (530) 752-9759; 
www.vetmed.ucdavis.edu/clinicaltrials/

University of Minnesota

The Veterinary Medical Center at the University of Minnesota is conducting a study in dogs with high-grade glioma including glioblastoma (GBM), common primary malignant brain tumors, to develop novel immunotherapy strategies that are more effective than current treatments.  These tumors are uniformly deadly in both dogs and people with median survival times of a few months in dogs and ~ 14 months in people after standard of care treatment. This work aims to evaluate novel combinations of immune therapies in dogs with previously untreated brain tumors to determine the combination that provides the longest remission times with minimal adverse effects. Our ultimate goal is to develop a safe and effective postoperative treatment that avoids the standard therapy with chemotherapy and radiation therapy that can be translated to human GBM patients.

Principle Investigators:

Dr. Liz Pluhar (PI), veterinary surgeon trained in neurosurgery, Veterinary Medical Center at the University of Minnesota

Dr. Michael Olin (co-I), veterinary immunologist developing vaccine-based immunotherapies, Masonic Cancer Center at the University of Minnesota

Dr. Maria Castro (co-I), research scientist in neuroimmunology developing viral-mediated gene therapies, Medical School at the University of Michigan